Small-molecule-based targeted therapy in liver cancer

Y Ming, Y Gong, X Fu, X Ouyang, Y Peng, W Pu - Molecular Therapy, 2024 - cell.com
Liver cancer is one of the most prevalent malignant tumors worldwide. According to the
Barcelona Clinic Liver Cancer staging criteria, clinical guidelines provide tutorials to clinical …

Heterocycles‐Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years

A Raucci, C Castiello, A Mai, C Zwergel… - …, 2024 - Wiley Online Library
Cancer is one of the primary causes of mortality worldwide. Despite nowadays are
numerous therapeutic treatments to fight tumor progression, it is still challenging to …

Discovery of a novel CDK4/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma

Z Niu, Z Shi, G Wu, Y Liu, W Xie, F Liu, T Fan, K Shu… - Bioorganic …, 2024 - Elsevier
The down-regulation of p21 after long-term CDK4/6 inhibition represents a key mechanism
causing resistance to CDK4/6 inhibitors in some tumor cells, while the HDAC inhibitor could …